Mindfulness Meditation vs Escitalopram for Treatment of Anxiety Disorders: Secondary Analysis of a Randomized Clinical Trial

Hiroe Hu; Mihriye Mete; Neil K Rustgi; Charisma I Washington; Kavya Sanghavi; Mary Ann Dutton; Naomi M Simon; Amanda W Baker; Eric Bui; Elizabeth A Hoge

doi:10.1001/jamanetworkopen.2024.38453

Mindfulness Meditation vs Escitalopram for Treatment of Anxiety Disorders: Secondary Analysis of a Randomized Clinical Trial

JAMA Netw Open. 2024 Oct 1;7(10):e2438453. doi: 10.1001/jamanetworkopen.2024.38453.

Authors

Affiliations

¹ Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
² Medstar Health Research Institute, Hyattsville, Maryland.
³ Department of Psychiatry, Georgetown University Medical Center, Washington, DC.
⁴ Department of Psychiatry, NYU Grossman School of Medicine, New York.
⁵ Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
⁶ Caen University Hospital, University of Caen Normandy, Caen, France.

No abstract available

Plain language summary

This secondary analysis of a randomized clinical trial assesses patient-reported anxiety, depression, and quality of life among patients receiving mindfulness-based stress reduction vs escitalopram for the treatment of anxiety disorders.

Publication types

Randomized Controlled Trial

MeSH terms

Adult
Anxiety Disorders* / drug therapy
Anxiety Disorders* / therapy
Citalopram / therapeutic use
Escitalopram* / therapeutic use
Female
Humans
Male
Meditation* / methods
Middle Aged
Mindfulness* / methods
Selective Serotonin Reuptake Inhibitors / therapeutic use
Treatment Outcome

Substances

Escitalopram
Selective Serotonin Reuptake Inhibitors
Citalopram